We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+3.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$957M
AUM Growth
+$1.08M
Cap. Flow
-$9.87M
Cap. Flow %
-1.03%
Top 10 Hldgs %
32.99%
Holding
140
New
9
Increased
34
Reduced
55
Closed
6

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$11.5M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$9.5M
3
ONC
BeOne Medicines Ltd
ONC
+$9.49M
4
INCY icon
Incyte
INCY
+$8.91M
5
CELG
Celgene Corp
CELG
+$8.11M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$20.7M
2
GILD icon
Gilead Sciences
GILD
+$16.8M
3
ABMD
Abiomed Inc
ABMD
+$10.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$8.6M
5
ABBV icon
AbbVie
ABBV
+$7.85M

Sector Composition

Rank Sector Weight
1 Healthcare 95.72%
2 Financials 0.41%
3 Industrials 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$42.2M 4.41%
404,265
+71,896
+22% +$8.11M
ELV icon
2
Elevance Health
ELV
$80.9B
$40.8M 4.26%
181,243
+10,100
+6% +$2.15M
ALGN icon
3
Align Technology
ALGN
$12.7B
$38.6M 4.03%
173,596
-19,150
-10% -$4.35M
ISRG icon
4
Intuitive Surgical
ISRG
$122B
$35.1M 3.67%
288,393
+15,000
+5% +$1.88M
ILMN icon
5
Illumina
ILMN
$28.2B
$32.7M 3.42%
154,069
-14,035
-8% -$2.89M
UNH icon
6
UnitedHealth
UNH
$387B
$31.5M 3.29%
142,910
+6,640
+5% +$1.41M
ABT icon
7
Abbott
ABT
$175B
$30.2M 3.16%
530,000
+27,000
+5% +$1.5M
INCY icon
8
Incyte
INCY
$23.4B
$21.9M 2.29%
231,576
+85,210
+58% +$8.91M
WBA
9
DELISTED
Walgreens Boots Alliance
WBA
$21.5M 2.25%
296,560
+34,500
+13% +$2.43M
EW icon
10
Edwards Lifesciences
EW
$49.4B
$21.2M 2.22%
564,600
-52,980
-9% -$1.94M
JAZZ icon
11
Jazz Pharmaceuticals
JAZZ
$15.5B
$20.9M 2.19%
155,582
+40,330
+35% +$5.59M
HOLX
12
DELISTED
Hologic
HOLX
$20.7M 2.16%
483,894
+120,793
+33% +$4.82M
LLY icon
13
Eli Lilly
LLY
$1.05T
$20.4M 2.13%
241,262
– –
COR icon
14
Cencora
COR
$59.9B
$19.4M 2.02%
210,941
+12,950
+7% +$1.07M
DHR icon
15
Danaher
DHR
$144B
$18.8M 1.96%
227,856
+48,730
+27% +$3.96M
MDT icon
16
Medtronic
MDT
$106B
$17.5M 1.83%
217,000
– –
BSX icon
17
Boston Scientific
BSX
$65.4B
$17.3M 1.8%
696,000
– –
BIIB icon
18
Biogen
BIIB
$30.4B
$16.7M 1.74%
52,300
-6,600
-11% -$2.12M
ALXN
19
DELISTED
Alexion Pharmaceuticals
ALXN
$15.6M 1.63%
130,770
+44,770
+52% +$5.45M
DXCM icon
20
DexCom
DXCM
$29.6B
$15.3M 1.6%
1,066,960
+886,960
+493% +$11.5M
VRTX icon
21
Vertex Pharmaceuticals
VRTX
$123B
$14.4M 1.51%
96,210
+36,410
+61% +$5.39M
HRC
22
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$14.3M 1.5%
169,939
– –
AMGN icon
23
Amgen
AMGN
$198B
$14.2M 1.49%
81,750
-116,895
-59% -$20.7M
SYK icon
24
Stryker
SYK
$123B
$14.1M 1.48%
91,300
+7,000
+8% +$1.07M
BAX icon
25
Baxter International
BAX
$11.7B
$14M 1.46%
216,000
– –
1
2 3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q4 2017 Portfolio in Review

As of Q4 2017, Bellevue Group held 140 positions worth $957M, up 0.11% from $956M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Bellevue Group's Q4 2017 filing shows 9 new, 34 increased, 55 reduced and 6 closed positions. Its largest new stake was Supernus Pharmaceuticals: 240,400 shares worth $9.58M. The largest sale was Amgen, an estimated $20.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Financials and Industrials.

  • Bellevue Group's largest Q4 2017 buy was Supernus Pharmaceuticals: 240,400 shares worth $9.58M.
  • Bellevue Group added most to DexCom in Q4 2017, an estimated $11.5M increase.
  • Bellevue Group's biggest Q4 2017 reduction was Amgen, cutting an estimated $20.7M.
  • Bellevue Group fully exited MALLINCKRODT PUBLIC LIMITED COMPANY in Q4 2017, selling an estimated $8.6M.
  • Bellevue Group's ten largest holdings make up 33% of its $957M portfolio in Q4 2017.
  • Bellevue Group opened 9 new positions and closed 6 in Q4 2017.
  • Bellevue Group's portfolio value rose 0.11% quarter-over-quarter to $957M.

Based on Bellevue Group's 13F filing for Q4 2017, filed 14 Feb 2018.